FDA Highlights by Bruce Sylvester – Patients suffering chemotherapy-induced peripheral neuropathy treated with the anti-depressant duloxetine for 5 weeks achieved a greater reduction in pain compared with patients… read more.
by Bruce Sylvester – taken from the BMJ – Researchers have reported a significant decline in the proportion of young women diagnosed with genital warts in Australia following… read more.
Researchers reported encouraging but preliminary results of gene-based immune therapy in two children with relapsed and refractory acute lymphoblastic leukemia (ALL).
Significant benefit also seen in men. The proportion of young women diagnosed with genital warts in Australia has seen a significant decline thanks to the HPV vaccine, say… read more.
by Maria Dalby reporting on the presentation by Dion Morton, Experimental Cancer Medicine Centre, University of Birmingham & Sir Peter John Morris, Centre for Evidence in Transplantation, Royal… read more.
Effects reduced by up to 30 percent by low-vitamin D season. For women diagnosed with oestrogen receptor positive (ER+) breast cancer, tamoxifen is an essential drug used in… read more.
by Maria Dalby reporting on the presentation by Rajeev Desai, National Health Service Blood and Transplant, Bristol. The risk of cancer transmission via transplanted organs is very low… read more.
Results from a landmark study of specially formulated niacin in 25,673 high-risk patients appears to have extinguished any clinical role for niacin to reduce the risk of cardiovascular… read more.
Scotland takes action to tackle relationship between deprivation and CVD. Deprivation represents the “elephant in the room” with regard to cardiovascular disease (CVD), and health care professionals have… read more.
Researchers have found that macrophages that play a key role in the immune response – also help to both produce and eliminate the body’s red blood cells (RBCs)…. read more.
Advocates and pain management groups aired concerns recently over a citizen petition to change opioid labeling during the first of a 2-day FDA hearing.
The FDA has approved a selective estrogen receptor modulator (SERM) for treating pain associated with sexual intercourse in postmenopausal women.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
